A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 16 Mar 2018
At a glance
- Drugs Crizotinib (Primary) ; Iobenguane (Primary) ; Aldesleukin; Busulfan; Carboplatin; Cisplatin; Cyclophosphamide; Dexrazoxane; Dinutuximab; Doxorubicin; Etoposide phosphate; Isotretinoin; Melphalan; Sargramostim; Thiotepa; Topotecan; Vincristine
- Indications Neuroblastoma
- Focus Therapeutic Use
- 09 Mar 2018 Planned initiation date changed from 1 Dec 2017 to 2 Apr 2018.
- 08 Sep 2017 Planned initiation date changed from 1 Aug 2017 to 1 Dec 2017.
- 27 Apr 2017 New trial record